Text Size

Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

This study is currently recruiting participants.
Verified April 2013 by Forest Laboratories
Sponsor:
Collaborator:
Gedeon Richter Ltd.
Information provided by (Responsible Party):
Forest Laboratories
ClinicalTrials.gov Identifier:
NCT01396447
First received: July 15, 2011
Last updated: April 30, 2013
Last verified: April 2013
History of Changes

July 15, 2011
April 30, 2013
July 2011
October 2013   (final data collection date for primary outcome measure)
Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Week 6 to Week 8 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01396447 on ClinicalTrials.gov Archive Site
Clinical Global Impressions - Severity (CGI-S) [ Time Frame: Week 6 to Week 8 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression
A Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of patients with bipolar depression.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Depression, Bipolar
  • Drug: Placebo
    Patients who meet eligibility criteria will be administered a once daily oral dose of placebo
  • Drug: Cariprazine
    Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine
  • Placebo Comparator: 1
    Placebo
    Intervention: Drug: Placebo
  • Experimental: 2
    Cariprazine, 0.75 mg/day
    Intervention: Drug: Cariprazine
  • Experimental: 3
    Cariprazine, 1.5 mg/day
    Intervention: Drug: Cariprazine
  • Experimental: 4
    Cariprazine, 3.0 mg/day
    Intervention: Drug: Cariprazine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
November 2013
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who have provided informed consent prior to any study specific procedures
  • Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview for DSM-IV-TR (SCID) bipolar I depression without psychotic features
  • Patients with normal physical examination, laboratory, vital signs,and/ or ECG
  • Verified previous manic or mixed episode
  • Patients with a total Hamilton Rating Scale for Depression (HAMD)-17 score greater than or equal to 20
  • Patients with a HAMD-17 item 1 score greater than or equal to 2
  • Patients with a (Clinical Global Impression of Severity) CGI-S score of greater than or equal to 4

Exclusion Criteria:

  • Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months
Both
18 Years to 65 Years
No
Contact: Sandra Beaird, PhD 1-800-678-1605 ext 66297 info@forestpharm.com
United States,   Argentina,   Bulgaria,   Canada,   Russian Federation,   Ukraine
 
NCT01396447
RGH-MD-56, 2011-002334-39
No
Forest Laboratories
Forest Laboratories
Gedeon Richter Ltd.
Study Director: Robert Dunn, MD, PhD Forest Laboratories
Forest Laboratories
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP